<DOC>
	<DOCNO>NCT01843634</DOCNO>
	<brief_summary>This open-label pilot study evaluate safety preliminary evidence therapeutic effect ODSH ( 2-0 , 3-0 desulfated heparin ) conjunction standard induction consolidation therapy acute myeloid leukemia .</brief_summary>
	<brief_title>Ph I Safety Efficacy ODSH Patients Receiving Induction Consolidation Therapy Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Newly diagnose , previously untreated acute myeloid leukemia . Acute promyelocytic leukemia exclude . No prior chemotherapy acute myeloid leukemia ; however , prior hydroxyurea control white blood cell count allow . No prior chemotherapy lenalinomide treatment myelodysplastic syndrome . Age : 1870 . ECOG Performance status 02 Cardiac ejection fraction â‰¥ 50 % ( echocardiography MUGA [ multigated acquisition ] ) Adequate hepatic renal function ( AST [ aminotransferase ] , ALT [ alanine aminotransferase ] , bilirubin creatinine &lt; 2.5 x upper normal limit ) . Able provide inform consent sign approve consent form conform federal institutional guideline . Patients acute promyelocytic leukemia Patients acute megakaryoblastic leukemia Patients CNS ( central nervous system ) leukemia Presence significant active infection uncontrolled bleed Any coexist major illness organ failure contraindicate doseintensive chemotherapy regimen prescribe protocol Preexisting liver disease might impair ODSH clearance History active malignant disease within 5 year , cure basal cell carcinoma skin , cure situ carcinoma cervix , localized prostate cancer receive definitive therapy . Such prostate cancer patient receive hormonal therapy eligible Use recreational drug history drug addiction , within prior 6 month Known history positive hepatitis B surface antigens hepatitis C antibody Known history positive test HIV ( Human immunodeficiency virus ) antibodies Psychiatric neurologic condition could impair ability give proper inform consent Presence symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia Presence uncontrolled thrombotic hemorrhagic disorder A medical condition require need chronic anticoagulation Presence serious uncontrolled medical disorder Treatment investigational agent , participation another clinical trial within 28 day prior study entry Pregnant breastfeeding patient Patient childbearing potential use adequate contraception Hemorrhage risk require maintenance platelet count 50,000/uL high . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>